Anlon Healthcare has entered a phase where its growth story is becoming much bigger than its current size. The company is expanding its API and pharmaceutical-intermediate business, adding new products, building capacity and entering higher-margin CDMO opportunities. At the same time, its recent numbers show a sharp improvement in revenue and profit.
This is where the comparison with Cupid becomes interesting. Cupid has also seen a strong rise in revenue and profits, followed by a sharp re-rating in its stock. Anlon is still at an earlier stage of its growth journey, but management has given ambitious targets for the next few years. The key question is whether Anlon can deliver these targets and create the earnings growth needed for another major move in the stock.
Also read: JSW Energy’s 5 GWh BESS Plant Is Ready; When Will Its Battery Business Start Earning Revenue?
With a market cap of Rs 1,800 crore, the shares of Anlon Healthcare Ltd are trading at Rs 35 and are trading at a PE of 58 compared to their industry’s PE of 35. The shares have given a return of more than 250% since September 2025.
The Growth Story Is Picking Up
The reported revenues for the FY26 are at Rs 172 crore, representing growth from the prior year’s figure of Rs 120 crore. Profits before tax are up from Rs 32 crore to Rs 48 crore, and after-tax profits grew from Rs 21 crore to Rs 29 crore. Therefore, it can be stated that some growth was being experienced even before the current round of expansion initiatives took effect.
The dramatic turnaround comes through in management guidance as well. Revenues for FY27 are forecast at Rs 380 crore to Rs 400 crore, which represents almost double the level of FY26 revenues. In subsequent years, management guidance indicates revenue numbers of Rs 700 crore in FY28 and Rs 800 crore to Rs 900 crore in FY29. It is noteworthy that the FY29 figure is not entirely reflective of contributions from CDMO projects.
Why Cupid Comparison Matters
The rationale for comparing Cupid stems primarily from observing the growth trend evident in the financials. As shown above in the graph, the company grew revenues from around Rs 120 crore in FY25 to Rs 172 crore in FY26. Its operating profits moved up from Rs 32 crore to Rs 48 crore during this period. Importantly, however, Cupid has started exhibiting accelerated growth rates on a quarterly basis.
In many ways, Anlon appears to be at the start of such a phase, whereby a low base of revenue is beginning to exhibit significantly faster growth rates. For instance, the company’s Q1 FY27 sales stood at Rs 87.6 crore as against Rs 33.3 crore in Q1 FY26. Operating profits went up from Rs 6.2 crore to Rs 15.6 crore, while its net profits climbed from Rs 3.6 crore to Rs 8.3 crore. These numbers illustrate acceleration trends but do not necessarily predict similar stock movements.
Can Margins Improve?
Revenue growth alone will not suffice. There is also the need to preserve margins for Anlon. The firm has seen a significant spike in the cost of raw materials, with management highlighting that some solvent costs rose above 200%-300%. Nonetheless, it seems that it has begun recovering some of these additional expenses from customers. Management indicated that it has gained an extra 15%-20% in pricing from customers.
Also read: ₹98 Crore to ₹350 Crore: How Will Neetu Yoshi Deliver on Its 257% Revenue Growth Target?
Management expects the firm to see EBITDA margins in the range of 27%-28% for Anlon Healthcare and Bizotic. Moreover, it anticipates that the business will largely stick to its projected EBITDA and PAT margins for FY27. Such projections are critical since any combination of higher revenues and stable margins will facilitate much more rapid profit growth compared to historical trends.
Capacity Is the Next Trigger
Anlon is expanding production capacity too. The construction project for this purpose has begun, with plans to complete the setup in Q2 FY28. As per management estimates, utilisation rates would start at around 40–45% and progressively go up to 60–65%.
This expansion becomes critical for several reasons.
Based purely on the numbers, the existing facilities could fall short of meeting its stated revenue guidance goals without any capacity expansion. The planned new facility would have roughly four times the capacity of the existing 400 tonnes per year NM capacity facility. Secondly, the facility is multi-product, meaning Anlon could manufacture various APIs, DMFs and other products through the new facility based on demand.
CDMO Could Be the Bigger Opportunity
One unique angle in the story is that Anlon has been working with three different molecules for two different global innovators via CDMO services. The first molecule is currently undergoing validation and should be ready for commercialisation by about January 2028, while validation batches of the remaining two molecules will be delivered between October-November.
The relevance here lies in margins. The management anticipates an EBITDA margin of at least 45-50% on its first molecule due for commercialisation from the CDMO business. While there are no estimates available for the remaining two molecules currently in early stages, successful commercialisation of these molecules would help augment profits for the business.
What is critical is that the management itself acknowledges that it hasn’t considered the complete scope of the CDMO opportunity when providing its earnings guidance range of Rs 800–900 crores for FY29.
Cash Flow Cannot Be Ignored
Investors should pay close attention to Anlon’s cash flows, given that its business involves high working capital needs due to the inventory holding required by its pharmaceutical-manufacturing operations. Management estimates that within FY27, its receivable days would fall to around 170–180 days and its inventory days to around 140–150 days. Management further believes that it would achieve positive cash flow within FY27.
Also read: Can Allied Blenders’s Premiumization and Backward Integration Drive EBITDA Margins From 14.4% to 18%?
The importance here lies in how Anlon’s cash flows would develop along with increasing revenue to approximately Rs 800–900 crore from current levels of Rs 380 crore. Higher working capital needs at higher revenues imply that there may be limitations on working capital financing from existing sources, as stated by management itself. Higher revenue without corresponding cash collections might therefore be concerning.
Is Anlon the Next Cupid?
Anlon possesses some elements that may contribute to the next phase of growth, including sharply increasing revenues, added capacity, an expanding product portfolio, improved margins and a potential margin-rich CDMO business. Management sees Rs 380-400 crore of revenues by FY27, Rs 700 crore by FY28 and Rs 800-900 crore by FY29. The fact that the full upside of the CDMO opportunity does not factor into the long-term guidance suggests that there might still be more upside in the offing.
It would be wrong to infer that merely being compared to Cupid implies that Anlon will generate returns for its investors in terms of stock-market performance. In order to realise such an outcome, a number of factors need to fall in place: meeting guidance for FY27, maintaining robust margins amid volatile raw material prices, scaling capacity at its new plant, optimising working capital and successfully transitioning its CDMO opportunities from validation to commercialisation phases. Should these factors come together to produce sustained earnings growth, Anlon will be able to produce a compelling growth narrative worth another large valuation re-rating.
Also read: Endurance Technologies Trades 24% Below Industry P/E: Can Its EV Push Unlock More Value?